Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 372 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemodialysis Patients Clear all
Completed Phase 4 Interventional

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)

NCT00224081
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis
Interventions
Sodium ferric gluconate,
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
29
States / cities
Bakersfield, California • Glendale, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

NCT01628120
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
115
States / cities
Azusa, California • Bakersfield, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 6, 2026, 10:47 AM EDT
Not listed Phase 4 Interventional

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

NCT01731301
View directory record Official record
Conditions
Chronic Hepatitis C, End Stage Renal Disease
Interventions
Ribavirin, Peginterferon, Boceprevir
Drug
Lead sponsor
Liver Institute of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients

NCT02145260
View directory record Official record
Conditions
Intra-dialytic Hypotension
Interventions
Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate), Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 6, 2026, 10:47 AM EDT
Terminated Phase 4 Interventional

Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias

NCT01623583
View directory record Official record
Conditions
Needle Phobia, Phobic Disorders
Interventions
Enhanced Needle Phobia Intervention, Standard Needle Phobia Intervention
Other
Lead sponsor
Davita Clinical Research
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Rancho Cordova, California • Sacramento, California • Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Pilot Study Using a Pulse Oximeter Derived Photo-plethysmographic Waveform to Guide Hemodialysis Ultrafiltration

NCT02264522
View directory record Official record
Conditions
Intradialytic Hypotension, Hypervolemia
Interventions
Place dialysis chair into position 3., Decrease dialysate temperature., Decrease ultrafiltration rate by 25%., Decrease ultrafiltration rate by 50%.
Other
Lead sponsor
Intelomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

NCT04484857
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Peginesatide for Anemia in Chronic Hemodialysis Patients

NCT00228449
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Behavioral Management of Phosphorus in Hemodialysis Patients

NCT02940743
View directory record Official record
Conditions
Cardiovascular Disease (CKD), Hyperphosphatemia
Interventions
Education (Edu), SM intervention, Social Cognitive Therapy (SCT)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 6, 2026, 10:47 AM EDT
Not listed No phase listed Observational

Measuring Cardiovascular Stress in Patients on Hemodialysis Study II

NCT02182089
View directory record Official record
Conditions
Hypotension of Hemodialysis, Hypotension, Estimated Dry Weight, Myocardial Injury, Arrhythmia
Interventions
Not listed
Lead sponsor
Intelomed, Inc.
Industry
Eligibility
20 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 6, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients

NCT04163614
View directory record Official record
Conditions
End Stage Renal Disease, Hypertension, Extracellular Volume Overload, Intradialytic Hypotension
Interventions
IBPS-Guided Ultrafiltration
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Triferic Pediatric Pharmacokinetic Protocol

NCT02595437
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 6, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT04671771
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Kidney Failure, Chronic Renal Disease, Hemodialysis
Interventions
InnAVasc Arteriovenous Graft (IG) surgical implant
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 90 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Sarasota, Florida • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Improving Outcomes for Hemodialysis Patients

NCT03395366
View directory record Official record
Conditions
Quality of Life, End Stage Renal Disease
Interventions
Multifaceted Educational / Cognitive Behavioral Intervention
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 6, 2026, 10:47 AM EDT
Terminated Phase 1 Interventional

Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension

NCT00237783
View directory record Official record
Conditions
Hemodialysis, Hypotension
Interventions
dialysate sodium (140 mmol/L), individualized dialysate sodium
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 6, 2026, 10:47 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

NCT02661295
View directory record Official record
Conditions
End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
Interventions
Ferric Citrate
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 6, 2026, 10:47 AM EDT
Completed No phase listed Observational

T Wave Alternans in Hemodialysis

NCT00296543
View directory record Official record
Conditions
End Stage Renal Disease, Coronary Heart Disease, Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Not applicable Interventional

A Study AnalyZing a NovEl Wearable SeNsor for Remote PatIent Health Monitoring

NCT03993886
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Diseases
Interventions
CorBand, Activity Monitor, Bioimpedance spectrometer, ECG, respiratory rate sensor
Device · Other
Lead sponsor
ReThink Medical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Francisco, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

NCT01788046
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
45
States / cities
Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

NCT01958970
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Disease, Protein Energy Wasting
Interventions
PINTA 745, Placebo
Drug
Lead sponsor
Pinta Biotherapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High-Protein Food Snack for Dialysis Patients

NCT04134377
View directory record Official record
Conditions
Renal Failure, Albumin; Double, Diet Habit
Interventions
Protein Food Snack
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

NCT02453646
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
NexSite HD Patients
Device
Lead sponsor
Marvao Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Greenville, North Carolina • New Bern, North Carolina • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 6, 2026, 10:47 AM EDT
Terminated Not applicable Interventional

Functional Electrical Stimulation (FES) Exercise Training in Hemodialysis Patients

NCT01956214
View directory record Official record
Conditions
Complication of Dialysis
Interventions
FES Exercise, Mock FES Exercise
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
31 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 6, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 6, 2026, 10:47 AM EDT